

## Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

Thomas C. Wehler · Claudine Graf · Markus Möhler · Jutta Herzog ·  
Martin R. Berger · Ines Gockel · Hauke Lang · Matthias Theobald ·  
Peter R. Galle · Carl C. Schimanski

Published online: 20 September 2013  
© Springer-Verlag Berlin Heidelberg 2013

**Erratum to: J Cancer Res Clin Oncol**  
**DOI 10.1007/s00432-013-1483-4**

The corresponding author would like to correct the Figs. 1 and 2 and its captions, which were published incorrectly in the original version.

The corrected figures and captions are presented below.

---

The online version of the original article can be found under doi:[10.1007/s00432-013-1483-4](https://doi.org/10.1007/s00432-013-1483-4).

---


T. C. Wehler (✉) · C. Graf · M. Theobald  
Third Department of Internal Medicine, Johannes Gutenberg  
University of Mainz, Mainz, Germany  
e-mail: thomas.wehler@unimedizin-mainz.de

M. Möhler · P. R. Galle · C. C. Schimanski  
First Department of Internal Medicine, Johannes Gutenberg  
University of Mainz, Mainz, Germany  
e-mail: c.schimanski@marienhospital-darmstadt.de

J. Herzog · C. C. Schimanski  
Department of Internal Medicine, Marienhospital Darmstadt,  
Martinspfad 72, 64285 Darmstadt, Germany

M. R. Berger  
Toxicology and Chemotherapy Unit, German Cancer Research  
Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg,  
Germany

I. Gockel · H. Lang  
Department of General and Abdominal Surgery, Johannes  
Gutenberg University of Mainz, Mainz, Germany



	Grade I	Grade II	Grade III	Grade IV
<b>definition</b> acneiform exanthema NCI CTCAE3.0	<b>asymptomatic</b>  <b>light</b> makulate/papular/pustular exanthema or erythema	<b>symptomatic</b> itching/ biting  <b>intermediate</b> makulate/papular/pustular exanthema or erythema  < 50 % of skin surface	<b>symptomatic</b> itching/ biting  <b>severe</b> makulate/papular/pustular exanthema or erythemam  > 50 % of skin surface	generalised exfoliative, ulcerative or bullous dermatitis

**Fig. 1** Cetuximab-associated acneiform exanthema. Cetuximab-associated acneiform exanthema is classified according NCI CTCAE3.0

**Fig. 2** Prophylactic treatment regimen applied to group B and reactive treatment regimen applied to group C

